HR 4597
116th Congress
House
Health
Health care costs and insurance
Medicare
Prescription drugs
ACCESS for Biosimilars Act of 2019
Introduced: October 1, 2019
Introduced by:
Peters, Scott H.
Democratic
· California
See on congress.gov
Everywhere this bill has been
4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 2, 2019
Referred to the Subcommittee on Health.
Oct 1, 2019
Referred to the Subcommittee on Health.
Oct 1, 2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Oct 1, 2019
Introduced in House
Plain-English summary
Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 or the ACCESS for Biosimilars Act of 2019
This bill eliminates cost-sharing for biosimilar biological products for certain qualifying beneficiaries under Medicare medical services. Specifically, the bill eliminates cost-sharing for beneficiaries whose coverage under private health insurance, a federal program (other than Medicare), a Medicare supplemental policy, or Medicare Advantage does not already do so. The Centers for Medicare & Medicaid Services must establish a process for determining a beneficiary's eligibility and notifying Medicare Advantage organizations of such determinations.
What's happening now
Referred to the Subcommittee on Health.
Committees of jurisdiction
4